Neurosarcoidosis: Diagnostic approaches and therapeutic strategies

Current Opinion in Neurology

Volumn 26, Issue 3, 2013, Pages 307-313

  Segal, Benjamin M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

neuroinflammation; neurosarcoidosis; T helper 1 cells

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB;

BRAIN DAMAGE; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CRANIAL NERVE; CRANIAL NEUROPATHY; FACIAL NERVE PARALYSIS; FEVER; FINLAND; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; PAROTID GLAND DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SARCOIDOSIS; SPINAL CORD LESION; SWEDEN; T LYMPHOCYTE ACTIVATION; THORAX RADIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TUBERCULOSIS; UNITED STATES; UVEITIS;

ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; SARCOIDOSIS;

EID: 84877706854     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283608459     Document Type: Review

References (89)

1. Nunes H, Bouvry D, Soler P, Valeyre D. Sarcoidosis. Orphanet J Rare Dis 2007; 2:46.
2. Pietinalho A, Hiraga Y, Hosoda Y, et al. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995; 12:61-67.
3. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145:234-241.
4. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. Epidemiology and clinical picture. Sarcoidosis 1990; 7:50-57.
5. Cozier YC, Berman JS, Palmer JR, et al. Reproductive and hormonal factors in relation to incidence of sarcoidosis in US Black women: The Black Women's Health Study. Am J Epidemiol 2012; 176:635-641.
6. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885-1889. (Pubitemid 33152325)
7. Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med 1977; 87:336-345. (Pubitemid 8177365)
8. Chapelon C, Ziza JM, Piette JC, et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990; 69:261-276. (Pubitemid 20360035)
9. Vargas DL, Stern BJ. Neurosarcoidosis: diagnosis and management. Semin Respir Crit Care Med 2010; 31:419-427.
10. Iwai K, Tachibana T, Takemura T, et al. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 1993; 43:372-376. (Pubitemid 23225816)
11. D'Errico S, Bello S, Cantatore S, et al. Immunohistochemical characterisation and TNF-alpha expression of the granulomatous infiltration of the brainstem in a case of sudden death due to neurosarcoidosis. Forensic Sci Int 2011; 208:e1-e5.
12. Stern BJ, Griffin DE, Luke RA, et al. Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations. Neurology 1987; 37:878-881. (Pubitemid 17064691)
13. Reske D, Petereit HF, Heiss WD. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system-value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 2005; 112:207-213. (Pubitemid 41337066)
14. Moller DR, Forman JD, LiuMC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156:4952-4960. (Pubitemid 26174485)
15. Agostini C, Facco M, Chilosi M, Semenzato G. Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation. Microsc Res Tech 2001; 53:278-287. (Pubitemid 32467165)
16. Bergeron A, Bonay M, Kambouchner M, et al. Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. J Immunol 1997; 159:3034-3043. (Pubitemid 127681328)
17. Kunkel SL, Lukacs NW, Strieter RM, Chensue SW. Animal models of granulomatous inflammation. Semin Respir Infect 1998; 13:221-228. (Pubitemid 28440841)
18. Nishiwaki T, Yoneyama H, Eishi Y, et al. Indigenous pulmonary Propionibacterium acnes primes the host in the development of sarcoid-like pulmonary granulomatosis in mice. Am J Pathol 2004; 165:631-639. (Pubitemid 38971392)
19. Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009; 80:297-304.
20. Gascon-Bayarri J, Mana J, Martinez-Yelamos S, et al. Neurosarcoidosis: report of 30 cases and a literature survey. Eur J Intern Med 2011; 22:e125-e132.
21. Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand 1986; 73:283-290. (Pubitemid 16124051)
22. Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42:909-917. (Pubitemid 15021583)
23. Szmulewicz DJ, Waterston JA. Two patients with audiovestibular sarcoidosis. J Clin Neurosci 2012; 19:158-161.
24. Cama E, Santarelli R, Muzzi E, et al. Sudden hearing loss in sarcoidosis: otoneurological study and neuroradiological correlates. Acta Otorhinolaryngol Ital 2011; 31:235-238.
25. Loor RG, van Tongeren J, Derks W. Multiple cranial nerve dysfunction caused by neurosarcoidosis. Am J Otolaryngol 2012; 33:484-486.
26. Colvin IB. Audiovestibular manifestations of sarcoidosis: a review of the literature. Laryngoscope 2006; 116:75-82. (Pubitemid 44383966)
27. Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102:449-460.
28. Zajicek JP, Scolding NJ, FosterO, et al. Central nervous system sarcoidosis-diagnosis and management. QJM 1999; 92:103-117. (Pubitemid 29097635)
29. Kellinghaus C, Schilling M, Ludemann P. Neurosarcoidosis: clinical experience and diagnostic pitfalls. Eur Neurol 2004; 51:84-88. (Pubitemid 38339721)
30. Stern BJ. Neurological complications of sarcoidosis. Curr Opin Neurol 2004; 17:311-316. (Pubitemid 38720985)
31. Langrand C, Bihan H, Raverot G, et al. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM 2012; 105:981-995.
32. Uruha A, Koide R, Taniguchi M. Unusual presentation of sarcoidosis: solitary intracranial mass lesion mimicking a glioma. J Neuroimag 2011; 21:e180-e182.
33. Tsao CY, Lo WD, Rusin JA, et al. Isolated neurosarcoidosis presenting as headache and multiple brain and spinal cord lesions mimicking central nervous system metastases. Brain Dev 2007; 29:514-518. (Pubitemid 47223606)
34. Lee JH, Takai K, Ota M, et al. Isolated neurosarcoidosis in the medulla oblongata involving the fourth ventricle: a case report. Br J Neurosurg, 2012. [Epub ahead of print]
35. John S, Parambil J, Culver D, Tavee J. Medullary neurosarcoidosis presenting with intractable hiccoughs. J Clin Neurosci 2012; 19:1193-1195.
36. Oishi A, Miyamoto K, Yoshimura N. Dorsal midbrain syndrome induced by midbrain neurosarcoidosis. Jpn J Ophthalmol 2008; 52:236-238.
37. Junger SS, Stern BJ, Levine SR, et al. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 1993; 43:333-337. (Pubitemid 23060264)
38. Sohn M, Culver DA, Judson MA, et al. Spinal cord neurosarcoidosis. Am J Med Sci 2013. [Epub ahead of print]
39. Sakushima K, Yabe I, Nakano F, et al. Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol 2011; 258:2163-2167.
40. Eby SA, Buchner EJ, Bryant MG. Presumed intramedullary spinal cord sarcoidosis in a healthy young adult woman. Am J Phys Med Rehabil 2012; 91:810-813.
41. Varron L, Broussolle C, Candessanche JP, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol 2009; 16:289-296.
42. Landi A, Di Norcia V, Dugoni DE, et al. Intramedullary nonspecific inflammatory lesion of thoracic spine: a case report. World J Surg Oncol 2010; 8:3.
43. Huang JF, Aksamit AJ, Staff NP. MRI and PET imaging discordance in neurosarcoidosis. Neurology 2012; 79:1070.
44. Navi BB, DeAngelis LM. Sarcoidosis presenting as brainstem ischemic stroke. Neurology 2009; 72:1021-1022.
45. Gonzalez-Aramburu I, Ruiz-Perez E, Gomez-Roman J, et al. Sarcoidosis presenting as transient ischemic attack status. J Stroke Cerebrovasc Dis 2012; 21:515-517.
46. Caplan L, Corbett J, Goodwin J, et al. Neuro-ophthalmologic signs in the angiitic form of neurosarcoidosis. Neurology 1983; 33:1130-1135. (Pubitemid 13002145)
47. O'Dwyer JP, Al-Moyeed BA, Farrell MA, et al. Neurosarcoidosis-related intracranial haemorrhage: three new cases and a systematic review of the literature. Eur J Neurol 2013; 20:71-78.
48. Herring AB, Urich H. Sarcoidosis of the central nervous system. J Neurol Sci 1969; 9:405-422.
49. Marangoni S, Argentiero V, Tavolato B. Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol 2006; 253:488-495. (Pubitemid 43965615)
50. Oksanen V, Fyhrquist F, Somer H, Gronhagen-Riska C. Angiotensin converting enzyme in cerebrospinal fluid: a new assay. Neurology 1985; 35:1220-1223. (Pubitemid 15003466)
51. Oksanen V, Fyhrquist F, Gronhagen-Riska C, Somer H. CSF angiotensinconverting enzyme in neurosarcoidosis. Lancet 1985; 1:1050-1051.
52. Tahmoush AJ, Amir MS, Connor WW, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:191-197.
53. Dale JC, O'Brien JF. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc 1999; 74:535. (Pubitemid 29207160)
54. Wahlbeck K, Rimon R, Fyhrquist F. Elevated angiotensin-converting enzyme (kininase II) in the cerebrospinal fluid of neuroleptic-treated schizophrenic patients. Schizophr Res 1993; 9:77-82. (Pubitemid 23076894)
55. Chan Seem CP, Norfolk G, Spokes EG. CSF angiotensin-converting enzyme in neurosarcoidosis. Lancet 1985; 1:456-457. (Pubitemid 15173155)
56. Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3:397-407. (Pubitemid 38789135)
57. Borucki SJ, Nguyen BV, Ladoulis CT, McKendall RR. Cerebrospinal fluid immunoglobulin abnormalities in neurosarcoidosis. Arch Neurol 1989; 46:270-273. (Pubitemid 19070224)
58. McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995; 58:548-554.
59. Scott TF, Seay AR, Goust JM. Pattern and concentration of IgG in cerebrospinal fluid in neurosarcoidosis. Neurology 1989; 39:1637-1639. (Pubitemid 20013605)
60. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49:1510-1517. (Pubitemid 37011740)
61. Miyoshi S, Hamada H, Kadowaki T, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 2010; 137:1391-1397.
62. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156:1586-1592. (Pubitemid 27505529)
63. Petereit HF, Reske D, Tumani H, et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 2010; 257:1855-1863.
64. Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol 2004; 182:289-295. (Pubitemid 38116564)
65. Shah R, Roberson GH, Curé JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol 2009; 30:953-961.
66. Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci 2011; 1:15.
67. Bolat S, Berding G, Dengler R, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 2009; 287:257-259.
68. Bartels S, Kyavar L, Blumstein N, et al. FDG PET findings leading to diagnosis of neurosarcoidosis. Clin Neurol Neurosurg 2013; 115:85-88.
69. Meenakshi M, Arnold C, Broadley SA. The value of [18F]- fluorodeoxyglucosepositron emission tomography/CT scanning in the diagnosis of neurosarcoidosis. J Clin Neurosci 2012; 19:1461-1462.
70. Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med 2010; 16:472-479.
71. Lacomis D. Neurosarcoidosis. Curr Neuropharmacol 2011; 9:429-436.
72. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72:337-340.
73. Chaussenot A, Bourg V, Chanalet S, et al. Neurosarcoidosis treated with mycophenolate mofetil: two cases. Rev Neurol (Paris) 2007; 163:471-475. (Pubitemid 46931925)
74. Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76:1168-1172.
75. Scott TF, Yandora K, Valeri A, et al. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol 2007; 64:691-696. (Pubitemid 46789835)
76. Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with infliximab. J Neurol Neurosurg Psychiatry 2010; 81:241-246.
77. Marnane M, Lynch T, Scott J, et al. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 2009; 256:139-140.
78. Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103:268-273.
79. Pereira J, Anderson NE, McAuley D, et al. Medically refractory neurosarcoidosis treated with infliximab. Intern Med J 2011; 41:354-357.
80. Toth C, Martin L, Morrish W, et al. Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. Acta Neurol Scand 2007; 116:259-262. (Pubitemid 47373480)
81. Sollberger M, Fluri F, Baumann T, et al. Successful treatment of steroidrefractory neurosarcoidosis with infliximab. J Neurol 2004; 251:760-761. (Pubitemid 38824027)
82. Matsumoto T, Nakamura I, Miura A, et al. New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol 2013; 32:271-275.
83. Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-a therapy: a French national survey. Rheumatology (Oxford) 2013. [Epub ahead of print]
84. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57:1885-1888. (Pubitemid 33096700)
85. Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75:568-570.
86. Malmgren K, Lycke J, Engman E, et al. Successful epilepsy surgery in a patient with neurosarcoidosis. Epilepsia 2010; 51:1101-1103.
87. Menninger MD, Amdur RJ, Marcus RB Jr. Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol 2003; 26:e115-e118.
88. Sundaresan P, Jayamohan J. Stereotactic radiotherapy for the treatment of neurosarcoidosis involving the pituitary gland and hypothalamus. J Med Imaging Radiat Oncol 2008; 52:622-626.
89. Bruns F, Pruemer B, Haverkamp U, Fischedick AR. Neurosarcoidosis: an unusual indication for radiotherapy. Br J Radiol 2004; 77:777-779. (Pubitemid 39386928)